Cheng Cui

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma

P. Hu, Qian Zhao, Ying Cheng, 2022, Frontiers in Pharmacology.

An UPLC–MS/MS method to determine CT‐707 and its two metabolites in plasma of ALK‐positive advanced non‐small cell lung cancer patients

Ji Jiang, P. Hu, Qian Zhao, 2018, Journal of pharmaceutical and biomedical analysis.

Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients

Ji Jiang, P. Hu, B. Du, 2021, Frontiers in Pharmacology.

An ultra HPLC-MS/MS method for quantification of hypidone hydrochloride (YL-0919) and application to a pharmacokinetic study.

Ji Jiang, P. Hu, Qian Zhao, 2019, Bioanalysis.

Simultaneous determination of FLZ and its metabolite (M1) in human plasma and urine by UHPLC‐MS/MS: Application to a pharmacokinetic study

Wei Wang, Ji Jiang, P. Hu, 2019, Journal of pharmaceutical and biomedical analysis.